checkAd
    Startseite > Aktien > Cabaletta Bio > Nachrichten
    Cabaletta Bio Aktie
    11,300
     
    USD
    +0,36 %
    +0,040 USD
    Letzter Kurs 15:40:52 Nasdaq
    11,190
     
    USD
    100 STK
    Geldkurs 15:40:55
    11,330
     
    USD
    100 STK
    Briefkurs 15:40:55
    ISIN: US12674W1099 · WKN: A2PTTB · SYM: CABA · USA

    Neueste Nachrichten

    Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
    13.05.24 · globenewswire · Cabaletta Bio
    Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
    21.03.24 · globenewswire · Cabaletta Bio
    Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis
    20.03.24 · globenewswire · Cabaletta Bio
    Cabaletta Bio to Participate in Upcoming Investor Conferences in March
    27.02.24 · globenewswire · Cabaletta Bio
    Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis
    01.02.24 · globenewswire · Cabaletta Bio
    Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
    31.01.24 · globenewswire · Cabaletta Bio
    Cabaletta Bio Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis
    08.01.24 · globenewswire · Cabaletta Bio
    Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference
    02.01.24 · globenewswire · Cabaletta Bio
    Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx Conference
    28.11.23 · globenewswire · Cabaletta Bio
    Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update
    09.11.23 · globenewswire · Cabaletta Bio
    Cellares and Cabaletta Bio Partner to Evaluate Automated Manufacturing for CABA-201, Cabaletta’s CD19-CAR T Cell Therapy on Cellares’ Cell Shuttle Platform
    06.11.23 · Business Wire (engl.) · Cabaletta Bio
    Cabaletta Bio Receives FDA Clearance of CABA-201 IND Application for Treatment of Generalized Myasthenia Gravis
    06.11.23 · globenewswire · Cabaletta Bio